Akèy › Kansè pwostat › Oklahoma › Oklahoma City
Etid klinik pou Kansè pwostat nan Oklahoma City, OK
21 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Oklahoma City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Ap rekriteFaz 3
- Oklahoma Proton Center, Oklahoma City
Protoacoustic Imaging For 3D Mapping
Ap rekriteEtid obsèvasyon
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- Hightower Clinical, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
Ap rekriteEtid obsèvasyon
- OU Health Stephenson Cancer Center, Oklahoma City
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
Ap rekrite
- University of Oklahoma HSC, Oklahoma City
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Ap rekriteEtid obsèvasyon
- OU Health Stephenson Cancer Center, Oklahoma City
Connect2Care: Prostate Cancer Education and Screenings for African American Men
Ap rekrite
- TSET Health Promotion Research Center, Oklahoma City
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #13, Oklahoma City
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Oklahoma City
- Kansè Poumon ki pa ti selil28 etid
- Kansè ovè28 etid
- Kansè Endomèt25 etid
- Kansè kolorektal22 etid
- Kansè poumon19 etid
- Kansè nan tete17 etid
- Kansè Metastatik16 etid
- Kansè (tout kalite)14 etid
- Leksemi mieloïd egi14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Kansè vejik11 etid
- Kansè pankreyas11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.